X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor

31Citations
Citations of this article
76Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The protein kinase ERK5 (MAPK7) is an emerging drug target for a variety of indications, in particular for cancer where it plays a key role mediating cell proliferation, survival, epithelial-mesenchymal transition, and angiogenesis. To date, no three-dimensional structure has been published that would allow rational design of inhibitors. To address this, we determined the X-ray crystal structure of the human ERK5 kinase domain in complex with a highly specific benzo[e]pyrimido[5,4-b]diazepine-6(11H)-one inhibitor. The structure reveals that specific residue differences in the ATP-binding site, compared to the related ERKs p38s and JNKs, allow for the development of ERK5-specific inhibitors. The selectivity of previously observed ERK5 inhibitors can also be rationalized using this structure, which provides a template for future development of inhibitors with potential for treatment of disease. © 2013 American Chemical Society.

Cite

CITATION STYLE

APA

Elkins, J. M., Wang, J., Deng, X., Pattison, M. J., Arthur, J. S. C., Erazo, T., … Knapp, S. (2013). X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. Journal of Medicinal Chemistry, 56(11), 4413–4421. https://doi.org/10.1021/jm4000837

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free